HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation
Soomin Ahn, Ji Won Woo, Kyoungyul Lee, So Yeon Park
J Pathol Transl Med. 2020;54(1):34-44.   Published online 2019 Nov 6     DOI: https://doi.org/10.4132/jptm.2019.11.03
Citations to this article as recorded by Crossref logo
UCNP-based Photoluminescent Nanomedicines for Targeted Imaging and Theranostics of Cancer
Evgenii L. Guryev, Anita S. Smyshlyaeva, Natalia Y. Shilyagina, Evgeniya A. Sokolova, Samah Shanwar, Alexey B. Kostyuk, Alexander V. Lyubeshkin, Alexey A. Schulga, Elena V. Konovalova, Quan Lin, Indrajit Roy, Irina V. Balalaeva, Sergey M. Deyev, Andrei V.
Molecules.2020; 25(18): 4302.     CrossRef
Impact of the Updated Guidelines on Human Epidermal Growth Factor Receptor 2 (HER2) Testing in Breast Cancer
Min Chong Kim, Su Hwan Kang, Jung Eun Choi, Young Kyung Bae
Journal of Breast Cancer.2020; 23(5): 484.     CrossRef
HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging
Betül Altunay, Agnieszka Morgenroth, Mohsen Beheshti, Andreas Vogg, Nicholas C. L. Wong, Hong Hoi Ting, Hans-Jürgen Biersack, Elmar Stickeler, Felix M. Mottaghy
European Journal of Nuclear Medicine and Molecular Imaging.2020;[Epub]     CrossRef